Sanofi Targets Accord Over Generic Taxotere

Law360, New York (January 7, 2011, 3:43 PM EST) -- Sanofi-Aventis US LLC has launched a suit seeking to stop Accord Healthcare Inc. USA from taking steps to market a generic copycat of cancer treatment Taxotere.

New Jersey-based Sanofi and Paris-based Aventis Pharma SA lodged a suit in the U.S. District Court for the District of Delaware on Thursday in response to Accord’s attempt to secure federal approval for a generic form of docetaxel, the active ingredient in Taxotere, before the expiration of two patents — the same patents that were invalidated in a related case...
To view the full article, register now.